NCT05970289 - Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 22, 2023

Primary Completion Date

July 16, 2025

Study Completion Date

February 28, 2026

Conditions

Chronic Hepatitis B Virus Infection

Interventions

BIOLOGICAL

PEG-IFNα

PEG-IFNα will be given via subcutaneous injection

DRUG

BRII-835

BRII-835 will be given via subcutaneous injection

Trial Locations (29)

2747

Investigative Site 61001, Kingswood

3004

Investigative Site 61003, Melbourne

4575

Investigative Site 61002, Birtinya

6351

Investigative Site 82003, Seoul

10041

Investigative Site 88602, Taipei

10330

Investigative Site 66003, Bangkok

11000

Investigative Site 66006, Nonthaburi

11217

Investigative Site 88603, Taipei

13496

Investigative Site 82005, Seoul

24253

Investigative Site 82002, Chuncheon

40002

Investigative Site 66005, Khon Kaen

41566

Investigative Site 82004, Daegu

49241

Investigative Site 82001, Busan

50200

nvestigative Site 66007, Chiang Mai

80756

Investigative Site 88601, Kaohsiung

90110

Investigative Site 66008, Songkhla

100000

Investigative Site 86001, Beijing

100050

Investigative Site 86001, Beijing

100069

Investigative Site 86007, Beijing

130021

Investigative Site 86008, Changchun

169856

Investigative Site 65001, Singapore

200025

Investigative Site 86013, Shanghai

310016

Investigative Site 86011, Hangzhou

400010

Investigative Site 86004, Chongqing

510630

Investigative Site 86006, Guangzhou

529889

Investigative Site 65002, Singapore

999077

Investigative Site 85201, Hong Kong

Investigative Site 85202, Hong Kong

05505

Investigative Site 82006, Soeul